All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type ECOG ⩾ 1 ECOG 0 ECOG 1 Gender, female Gender, male Hemoglobin concentration < 10g/dl hemoglobin concentration > 10g/dl metastasis (liver ) metastasis (lymph node ) metastasis (visceral) PD-L1 < 1% PD-L1 < 10% PD-L1 < 5% PD-L1 > 1% PD-L1 > 10% PD-L1 > 5% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) PDL1 < 25% PDL1 >25% smoker (current or former) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
urothelial cancer (UC) - bladder cancer (BC), immune chekpoint inhibitors vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results DANUBE (D vs C - all population), 2020 0.99 [0.83; 1.18]
DANUBE (D vs C - PDL1>25%), 2020 0.89 [0.71; 1.11]
DANUBE (DT vs C - all population), 2020 0.85 [0.71; 1.01]
DANUBE (DT vs C - PDL1>25%), 2020 0.74 [0.59; 0.93]
IMvigor-010, 2021 0.85 [0.66; 1.09]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.83 [0.69; 1.00]
IMvigor-130 (At-arm B vs Ch-armC), 2020 1.02 [0.83; 1.25]
IMvigor-211 (all population), 2018 0.85 [0.73; 0.99]
IMvigor-211 (PDL1>1%), 2018 0.87 [0.72; 1.06]
IMvigor-211 (PDL1>5%), 2018 0.87 [0.63; 1.21]
JAVELIN Bladder 100 (all population), 2020 0.69 [0.56; 0.86]
JAVELIN Bladder 100 (PDL1>25%), 2020 0.56 [0.40; 0.79]
KEYNOTE-045 (all population), 2017 0.73 [0.59; 0.91]
KEYNOTE-045 (PDL1 CPS >10%), 2017 0.57 [0.37; 0.88]
KEYNOTE-361 (P vs C), 2021 0.92 [0.77; 1.10]
KEYNOTE-361 (PC vs C), 2021 0.86 [0.72; 1.02]
0.84 [0.78 ; 0.89 ] DANUBE (D vs C - all population), 2020, DANUBE (D vs C - PDL1>25%), 2020, DANUBE (DT vs C - all population), 2020, DANUBE (DT vs C - PDL1>25%), 2020, IMvigor-010, 2021, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018, JAVELIN Bladder 100 (all population), 2020, JAVELIN Bladder 100 (PDL1>25%), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-045 (PDL1 CPS >10%), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 16 35% 9,540 moderate critical deaths (OS) (extension)detailed results IMvigor-211 (all population), 2018 0.82 [0.71; 0.94]
IMvigor-211 (PDL1>5%), 2018 0.87 [0.64; 1.18]
JAVELIN Bladder 100 (all population), 2020 0.76 [0.63; 0.92]
JAVELIN Bladder 100 (PDL1>25%), 2020 0.69 [0.52; 0.91]
KEYNOTE-045 (all population), 2017 0.70 [0.57; 0.85]
0.77 [0.71 ; 0.84 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, JAVELIN Bladder 100 (all population), 2020, JAVELIN Bladder 100 (PDL1>25%), 2020, KEYNOTE-045 (all population), 2017 5 0% 2,765 moderate not evaluable PFS (extension)detailed results JAVELIN Bladder 100 (all population), 2020 0.54 [0.45; 0.64]
JAVELIN Bladder 100 (PDL1>25%), 2020 0.46 [0.36; 0.59]
KEYNOTE-045 (all population), 2017 0.96 [0.79; 1.16]
0.62 [0.40 ; 0.96 ] JAVELIN Bladder 100 (all population), 2020, JAVELIN Bladder 100 (PDL1>25%), 2020, KEYNOTE-045 (all population), 2017 3 93% 1,600 moderate not evaluable progression or deaths (PFS)detailed results DANUBE (D vs C - all population), 2020 0.77 [0.54; 1.09]
DANUBE (D vs C - PDL1>25%), 2020 1.24 [0.74; 2.08]
DANUBE (DT vs C - all population), 2020 1.23 [0.88; 1.72]
DANUBE (DT vs C - PDL1>25%), 2020 1.02 [0.62; 1.68]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.82 [0.70; 0.96]
IMvigor-211 (all population), 2018 0.89 [0.60; 1.32]
IMvigor-211 (PDL1>1%), 2018 0.86 [0.53; 1.39]
IMvigor-211 (PDL1>5%), 2018 1.01 [0.76; 1.35]
JAVELIN Bladder 100 (all population), 2020 0.62 [0.52; 0.74]
JAVELIN Bladder 100 (PDL1>25%), 2020 0.56 [0.43; 0.73]
KEYNOTE-045 (all population), 2017 0.98 [0.81; 1.19]
KEYNOTE-045 (PDL1 CPS >10%), 2017 0.89 [0.61; 1.29]
KEYNOTE-361 (P vs C), 2021 1.35 [1.12; 1.63]
KEYNOTE-361 (PC vs C), 2021 0.78 [0.65; 0.93]
0.89 [0.77 ; 1.03 ] DANUBE (D vs C - all population), 2020, DANUBE (D vs C - PDL1>25%), 2020, DANUBE (DT vs C - all population), 2020, DANUBE (DT vs C - PDL1>25%), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018, JAVELIN Bladder 100 (all population), 2020, JAVELIN Bladder 100 (PDL1>25%), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-045 (PDL1 CPS >10%), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 14 77% 7,971 moderate low RFS/DFSdetailed results CheckMate 274 (all population), 2017 0.72 [0.59; 0.88]
CheckMate 274 (PDL1>1%), 2017 0.55 [0.39; 0.78]
0.65 [0.51 ; 0.84 ] CheckMate 274 (all population), 2017, CheckMate 274 (PDL1>1%), 2017 2 40% 991 low not evaluable CRR detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.96 [1.21; 3.17]
1.96 [1.21 ; 3.17 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 851 NA not evaluable DCRdetailed results JAVELIN Bladder 100 (all population), 2020 1.85 [1.35; 2.54]
JAVELIN Bladder 100 (PDL1>25%), 2020 2.03 [1.31; 3.16]
1.91 [1.48 ; 2.47 ] JAVELIN Bladder 100 (all population), 2020, JAVELIN Bladder 100 (PDL1>25%), 2020 2 0% 1,058 moderate not evaluable DMFSdetailed results CheckMate 274 (all population), 2017 0.75 [0.59; 0.95]
CheckMate 274 (PDL1>1%), 2017 0.61 [0.42; 0.89]
0.71 [0.58 ; 0.86 ] CheckMate 274 (all population), 2017, CheckMate 274 (PDL1>1%), 2017 2 0% 991 low not evaluable DORdetailed results DANUBE (D vs C - all population), 2020 0.35 [0.20; 0.62]
DANUBE (D vs C - PDL1>25%), 2020 0.27 [0.13; 0.57]
DANUBE (DT vs C - all population), 2020 0.44 [0.25; 0.75]
DANUBE (DT vs C - PDL1>25%), 2020 0.38 [0.19; 0.75]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.70 [0.46; 1.08]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.21 [0.12; 0.37]
IMvigor-211 (all population), 2018 0.16 [0.07; 0.35]
IMvigor-211 (PDL1>1%), 2018 0.20 [0.08; 0.50]
IMvigor-211 (PDL1>5%), 2018 0.16 [0.04; 0.55]
KEYNOTE-045 (all population), 2017 4.66 [1.83; 11.87]
0.38 [0.23 ; 0.63 ] DANUBE (D vs C - all population), 2020, DANUBE (D vs C - PDL1>25%), 2020, DANUBE (DT vs C - all population), 2020, DANUBE (DT vs C - PDL1>25%), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 10 82% 1,899 moderate low events or deaths (EFS)detailed results CheckMate 274 (all population), 2017 0.70 [0.55; 0.90]
CheckMate 274 (PDL1>1%), 2017 0.55 [0.35; 0.86]
IMvigor-010, 2021 0.89 [0.74; 1.08]
0.74 [0.58 ; 0.95 ] CheckMate 274 (all population), 2017, CheckMate 274 (PDL1>1%), 2017, IMvigor-010, 2021 3 60% 1,800 low not evaluable objective responses (ORR)detailed results DANUBE (D vs C - all population), 2020 0.36 [0.26; 0.49]
DANUBE (D vs C - PDL1>25%), 2020 0.41 [0.27; 0.62]
DANUBE (DT vs C - all population), 2020 0.59 [0.43; 0.80]
DANUBE (DT vs C - PDL1>25%), 2020 0.94 [0.64; 1.39]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.15 [0.88; 1.51]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.38 [0.28; 0.53]
IMvigor-211 (all population), 2018 0.99 [0.68; 1.45]
IMvigor-211 (PDL1>1%), 2018 0.95 [0.61; 1.49]
IMvigor-211 (PDL1>5%), 2018 1.07 [0.58; 2.00]
JAVELIN Bladder 100 (all population), 2020 7.46 [2.53; 21.97]
JAVELIN Bladder 100 (PDL1>25%), 2020 12.70 [2.11; 76.32]
KEYNOTE-045 (all population), 2017 2.08 [1.29; 3.34]
KEYNOTE-045 (PDL1 CPS >10%), 2017 3.86 [1.43; 10.46]
KEYNOTE-361 (P vs C), 2021 0.53 [0.39; 0.74]
KEYNOTE-361 (PC vs C), 2021 1.48 [1.10; 2.00]
1.00 [0.71 ; 1.41 ] DANUBE (D vs C - all population), 2020, DANUBE (D vs C - PDL1>25%), 2020, DANUBE (DT vs C - all population), 2020, DANUBE (DT vs C - PDL1>25%), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018, JAVELIN Bladder 100 (all population), 2020, JAVELIN Bladder 100 (PDL1>25%), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-045 (PDL1 CPS >10%), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 15 90% 8,731 moderate critical objective responses (ORR) (extension)detailed results KEYNOTE-045 (all population), 2017 2.16 [1.34; 3.48]
KEYNOTE-045 (PDL1 CPS >10%), 2017 3.56 [1.30; 9.71]
2.37 [1.54 ; 3.65 ] KEYNOTE-045 (all population), 2017, KEYNOTE-045 (PDL1 CPS >10%), 2017 2 0% 706 moderate not evaluable AE (any grade)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.34 [0.43; 12.83]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.14 [0.05; 0.40]
IMvigor-211 (all population), 2018 0.38 [0.17; 0.88]
IMvigor-211 (PDL1>5%), 2018 0.67 [0.11; 4.10]
JAVELIN Bladder 100 (all population), 2020 13.83 [6.28; 30.48]
KEYNOTE-045 (all population), 2017 0.28 [0.10; 0.75]
0.82 [0.16 ; 4.20 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017 6 93% 3,925 moderate not evaluable AE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.37 [0.27; 0.52]
DANUBE (DT vs C - all population), 2020 0.55 [0.40; 0.78]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.92 [0.63; 1.34]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.12 [0.08; 0.17]
IMvigor-211 (all population), 2018 0.80 [0.62; 1.04]
IMvigor-211 (PDL1>5%), 2018 1.38 [0.81; 2.33]
JAVELIN Bladder 100 (all population), 2020 3.85 [2.72; 5.44]
KEYNOTE-045 (all population), 2017 0.61 [0.43; 0.86]
0.70 [0.36 ; 1.38 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017 8 97% 5,236 moderate not evaluable AE (grade 3-5)detailed results KEYNOTE-361 (P vs C), 2021 0.38 [0.26; 0.54]
KEYNOTE-361 (PC vs C), 2021 1.53 [1.01; 2.33]
0.76 [0.19 ; 3.00 ] KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 2 96% 1,335 moderate not evaluable AE leading to death (grade 5)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.27 [0.70; 2.27]
IMvigor-130 (At-arm B vs Ch-armC), 2020 1.59 [0.88; 2.87]
IMvigor-211 (all population), 2018 0.91 [0.46; 1.79]
IMvigor-211 (PDL1>5%), 2018 0.73 [0.16; 3.34]
JAVELIN Bladder 100 (all population), 2020 4.03 [0.18; 89.68]
KEYNOTE-045 (all population), 2017 1.59 [0.65; 3.89]
KEYNOTE-361 (P vs C), 2021 3.49 [1.61; 7.56]
KEYNOTE-361 (PC vs C), 2021 3.74 [1.75; 7.95]
1.71 [1.14 ; 2.57 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 8 47% 5,260 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results DANUBE (D vs C - all population), 2020 0.66 [0.43; 1.03]
DANUBE (DT vs C - all population), 2020 1.51 [1.02; 2.22]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.05 [0.79; 1.40]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.13 [0.08; 0.21]
IMvigor-211 (all population), 2018 0.37 [0.24; 0.57]
IMvigor-211 (PDL1>5%), 2018 0.44 [0.20; 0.99]
JAVELIN Bladder 100 (all population), 2020 93.23 [5.71; 1522.42]
KEYNOTE-045 (all population), 2017 0.63 [0.35; 1.11]
KEYNOTE-361 (P vs C), 2021 0.85 [0.56; 1.29]
KEYNOTE-361 (PC vs C), 2021 2.02 [1.42; 2.89]
0.78 [0.45 ; 1.33 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 10 93% 6,590 moderate low AE leading to treatment discontinuation (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.85 [0.44; 1.65]
0.85 [0.44 ; 1.65 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable SAE (any grade)detailed results DANUBE (D vs C - all population), 2020 1.01 [0.74; 1.39]
DANUBE (DT vs C - all population), 2020 1.67 [1.23; 2.28]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.11 [0.85; 1.46]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.78 [0.59; 1.05]
IMvigor-211 (all population), 2018 0.92 [0.70; 1.19]
IMvigor-211 (PDL1>5%), 2018 1.79 [1.05; 3.05]
JAVELIN Bladder 100 (all population), 2020 1.55 [1.09; 2.21]
1.17 [0.94 ; 1.47 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, JAVELIN Bladder 100 (all population), 2020 7 72% 4,715 moderate not evaluable STRAE (any grade)detailed results DANUBE (D vs C - all population), 2020 0.50 [0.31; 0.81]
DANUBE (DT vs C - all population), 2020 1.57 [1.06; 2.32]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.33 [0.99; 1.80]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.41 [0.28; 0.60]
IMvigor-211 (all population), 2018 0.56 [0.40; 0.78]
IMvigor-211 (PDL1>5%), 2018 0.92 [0.48; 1.80]
JAVELIN Bladder 100 (all population), 2020 68.24 [4.16; 1120.28]
KEYNOTE-361 (P vs C), 2021 0.39 [0.26; 0.59]
KEYNOTE-361 (PC vs C), 2021 1.16 [0.83; 1.61]
0.82 [0.54 ; 1.25 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 9 88% 6,050 moderate not evaluable TRAE (any grade)detailed results CheckMate 274 (all population), 2017 2.84 [2.05; 3.92]
DANUBE (D vs C - all population), 2020 0.13 [0.09; 0.21]
DANUBE (DT vs C - all population), 2020 0.32 [0.20; 0.50]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.04 [0.53; 2.03]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.07 [0.04; 0.11]
IMvigor-211 (all population), 2018 0.28 [0.19; 0.40]
IMvigor-211 (PDL1>5%), 2018 0.38 [0.19; 0.79]
JAVELIN Bladder 100 (all population), 2020 290.72 [105.09; 804.24]
KEYNOTE-045 (all population), 2017 0.17 [0.10; 0.28]
KEYNOTE-361 (P vs C), 2021 0.08 [0.04; 0.14]
0.55 [0.19 ; 1.59 ] CheckMate 274 (all population), 2017, DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021 10 98% 6,589 moderate low TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.28 [0.95; 1.74]
DANUBE (D vs C - all population), 2020 0.10 [0.07; 0.15]
DANUBE (DT vs C - all population), 2020 0.25 [0.18; 0.35]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.02 [0.72; 1.43]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.04 [0.03; 0.06]
IMvigor-211 (all population), 2018 0.33 [0.25; 0.45]
IMvigor-211 (PDL1>5%), 2018 0.55 [0.31; 0.99]
JAVELIN Bladder 100 (all population), 2020 133.97 [8.24; 2178.15]
KEYNOTE-045 (all population), 2017 0.19 [0.12; 0.28]
KEYNOTE-361 (P vs C), 2021 0.08 [0.05; 0.12]
KEYNOTE-361 (PC vs C), 2021 1.19 [0.85; 1.67]
0.38 [0.18 ; 0.80 ] CheckMate 274 (all population), 2017, DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 11 97% 7,270 moderate low TRAE leading to death (grade 5)detailed results DANUBE (D vs C - all population), 2020 1.82 [0.16; 20.16]
DANUBE (DT vs C - all population), 2020 1.85 [0.17; 20.46]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.96 [0.60; 6.40]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.82 [0.18; 3.71]
IMvigor-211 (all population), 2018 0.42 [0.13; 1.39]
IMvigor-211 (PDL1>5%), 2018 0.98 [0.14; 7.10]
JAVELIN Bladder 100 (all population), 2020 0.16 [0.05; 0.46]
KEYNOTE-045 (all population), 2017 0.96 [0.24; 3.87]
KEYNOTE-361 (P vs C), 2021 1.13 [0.16; 8.10]
KEYNOTE-361 (PC vs C), 2021 0.98 [0.14; 7.00]
0.75 [0.41 ; 1.37 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 10 31% 6,571 moderate low TRAE leading to discontinuation (any grade)detailed results DANUBE (D vs C - all population), 2020 0.46 [0.26; 0.79]
DANUBE (DT vs C - all population), 2020 1.30 [0.83; 2.03]
IMvigor-211 (all population), 2018 0.22 [0.12; 0.38]
IMvigor-211 (PDL1>5%), 2018 0.37 [0.15; 0.92]
JAVELIN Bladder 100 (all population), 2020 73.11 [4.46; 1198.64]
KEYNOTE-045 (all population), 2017 0.48 [0.25; 0.93]
0.64 [0.29 ; 1.38 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017 6 87% 3,649 moderate not evaluable Abdominal pain TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
DANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53]
2.15 [0.19 ; 24.47 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020 2 0% 1,311 moderate not evaluable Acute kidney injury TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
DANUBE (D vs C - all population), 2020 0.45 [0.02; 13.55]
DANUBE (DT vs C - all population), 2020 2.78 [0.29; 26.84]
2.04 [0.41 ; 10.20 ] CheckMate 274 (all population), 2017, DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020 3 0% 2,010 moderate not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
DANUBE (DT vs C - all population), 2020 7.44 [0.39; 141.31]
JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
KEYNOTE-045 (all population), 2017 1.92 [0.06; 57.51]
KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
1.89 [0.49 ; 7.28 ] CheckMate 274 (all population), 2017, DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 7 0% 4,555 moderate serious Alopecia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35]
DANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53]
KEYNOTE-045 (all population), 2017 0.24 [0.01; 5.31]
0.67 [0.09 ; 4.84 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, KEYNOTE-045 (all population), 2017 3 0% 1,832 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.05 [0.02; 0.13]
DANUBE (DT vs C - all population), 2020 0.02 [0.01; 0.10]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.11 [0.67; 1.84]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.07 [0.02; 0.30]
IMvigor-211 (all population), 2018 0.40 [0.18; 0.89]
IMvigor-211 (PDL1>5%), 2018 0.98 [0.19; 4.97]
KEYNOTE-045 (all population), 2017 0.07 [0.02; 0.31]
KEYNOTE-361 (P vs C), 2021 0.02 [0.01; 0.07]
KEYNOTE-361 (PC vs C), 2021 0.87 [0.63; 1.20]
0.16 [0.06 ; 0.44 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 9 92% 5,882 moderate serious Arthralgia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
DANUBE (DT vs C - all population), 2020 5.56 [0.28; 111.52]
JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.54 [0.36 ; 17.86 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, JAVELIN Bladder 100 (all population), 2020 3 0% 2,000 moderate not evaluable Arthritis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
DANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15]
JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.24 [0.14 ; 10.65 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, JAVELIN Bladder 100 (all population), 2020 3 0% 2,000 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
DANUBE (D vs C - all population), 2020 0.25 [0.05; 1.24]
DANUBE (DT vs C - all population), 2020 0.65 [0.20; 2.08]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.00 [0.82; 4.92]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.63 [0.18; 2.15]
IMvigor-211 (all population), 2018 0.42 [0.18; 0.97]
IMvigor-211 (PDL1>5%), 2018 0.49 [0.04; 5.45]
JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
KEYNOTE-045 (all population), 2017 0.13 [0.02; 1.09]
KEYNOTE-361 (P vs C), 2021 0.12 [0.02; 0.98]
KEYNOTE-361 (PC vs C), 2021 0.98 [0.38; 2.50]
0.62 [0.37 ; 1.06 ] CheckMate 274 (all population), 2017, DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 11 34% 7,270 moderate low Blood creatinine increased TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
DANUBE (D vs C - all population), 2020 0.45 [0.02; 13.55]
DANUBE (DT vs C - all population), 2020 0.46 [0.02; 13.75]
0.74 [0.10 ; 5.30 ] CheckMate 274 (all population), 2017, DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020 3 0% 2,010 moderate not evaluable Chills TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.49 [0.25; 8.98]
DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
DANUBE (DT vs C - all population), 2020 7.44 [0.39; 141.31]
JAVELIN Bladder 100 (all population), 2020 4.03 [0.18; 89.68]
KEYNOTE-045 (all population), 2017 5.81 [0.29; 116.49]
KEYNOTE-361 (P vs C), 2021 4.58 [0.51; 41.18]
KEYNOTE-361 (PC vs C), 2021 1.97 [0.18; 21.78]
2.81 [1.08 ; 7.34 ] CheckMate 274 (all population), 2017, DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 7 0% 4,555 moderate not evaluable Constipation TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
DANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15]
IMvigor-211 (all population), 2018 0.02 [0.00; 0.38]
IMvigor-211 (PDL1>5%), 2018 0.12 [0.01; 2.28]
KEYNOTE-045 (all population), 2017 0.06 [0.00; 1.02]
KEYNOTE-361 (P vs C), 2021 1.13 [0.16; 8.10]
KEYNOTE-361 (PC vs C), 2021 0.24 [0.01; 5.43]
0.26 [0.07 ; 0.90 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 7 25% 4,295 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
DANUBE (D vs C - all population), 2020 0.68 [0.15; 3.05]
DANUBE (DT vs C - all population), 2020 0.69 [0.15; 3.10]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.59 [0.27; 25.03]
IMvigor-130 (At-arm B vs Ch-armC), 2020 2.21 [0.20; 24.48]
KEYNOTE-045 (all population), 2017 0.16 [0.01; 3.17]
KEYNOTE-361 (P vs C), 2021 0.38 [0.04; 3.63]
KEYNOTE-361 (PC vs C), 2021 0.32 [0.03; 3.14]
0.77 [0.37 ; 1.60 ] CheckMate 274 (all population), 2017, DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 8 0% 5,453 moderate not evaluable Dermatitis acneiform TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Diabetes TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
DANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15]
JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
1.47 [0.33 ; 6.48 ] CheckMate 274 (all population), 2017, DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 6 0% 4,034 moderate serious Diarrhoea TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 2.99 [0.31; 28.90]
DANUBE (D vs C - all population), 2020 0.36 [0.07; 1.86]
DANUBE (DT vs C - all population), 2020 1.67 [0.56; 5.05]
JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
KEYNOTE-045 (all population), 2017 1.44 [0.24; 8.71]
KEYNOTE-361 (P vs C), 2021 0.90 [0.24; 3.40]
KEYNOTE-361 (PC vs C), 2021 1.38 [0.43; 4.39]
1.20 [0.68 ; 2.12 ] CheckMate 274 (all population), 2017, DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 7 0% 4,555 moderate not evaluable Dry skin TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
DANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53]
2.15 [0.19 ; 24.47 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020 2 0% 1,311 moderate not evaluable Eczema TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
1.99 [0.07 ; 59.38 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Erythema TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
DANUBE (D vs C - all population), 2020 0.11 [0.01; 0.89]
DANUBE (DT vs C - all population), 2020 0.68 [0.23; 2.00]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.61 [0.70; 9.73]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.73 [0.12; 4.41]
IMvigor-211 (all population), 2018 0.37 [0.15; 0.88]
IMvigor-211 (PDL1>5%), 2018 2.00 [0.36; 11.15]
JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
KEYNOTE-045 (all population), 2017 0.25 [0.07; 0.92]
KEYNOTE-361 (P vs C), 2021 0.50 [0.15; 1.63]
KEYNOTE-361 (PC vs C), 2021 0.87 [0.33; 2.28]
0.66 [0.40 ; 1.08 ] CheckMate 274 (all population), 2017, DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 11 28% 7,270 moderate low Febrile neutropenia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.15 [0.01; 3.01]
DANUBE (DT vs C - all population), 2020 0.30 [0.03; 2.95]
IMvigor-211 (all population), 2018 0.04 [0.00; 0.27]
IMvigor-211 (PDL1>5%), 2018 0.09 [0.01; 1.75]
0.10 [0.03 ; 0.34 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 4 0% 2,439 moderate not evaluable Gastritis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
DANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15]
1.36 [0.10 ; 17.75 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020 2 0% 1,311 moderate not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 274 (all population), 2017 2.00 [0.50; 8.06]
2.00 [0.50 ; 8.06 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35]
DANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53]
JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
1.57 [0.20 ; 12.15 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, JAVELIN Bladder 100 (all population), 2020 3 0% 2,000 moderate not evaluable Hepatitis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 5.48 [0.27; 109.88]
DANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15]
KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
2.72 [0.53 ; 14.06 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 4 0% 2,646 moderate not evaluable Hypersensitivity TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.45 [0.02; 13.55]
DANUBE (DT vs C - all population), 2020 0.46 [0.02; 13.75]
0.46 [0.04 ; 5.04 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020 2 0% 1,311 moderate not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
DANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53]
JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
1.14 [0.24 ; 5.40 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 6 0% 3,856 moderate serious Hypophysitis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
DANUBE (DT vs C - all population), 2020 5.56 [0.28; 111.52]
KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
KEYNOTE-361 (PC vs C), 2021 5.92 [0.30; 118.67]
3.36 [0.66 ; 17.24 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 4 0% 2,646 moderate not evaluable Hypothyroidism TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
DANUBE (DT vs C - all population), 2020 3.70 [0.17; 82.33]
JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
KEYNOTE-361 (PC vs C), 2021 3.94 [0.18; 87.61]
2.47 [0.55 ; 11.04 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 5 0% 3,335 moderate serious Increase AST TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
DANUBE (D vs C - all population), 2020 0.91 [0.13; 6.48]
DANUBE (DT vs C - all population), 2020 1.85 [0.34; 10.18]
1.43 [0.43 ; 4.76 ] CheckMate 274 (all population), 2017, DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020 3 0% 2,010 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
DANUBE (D vs C - all population), 2020 2.74 [0.28; 26.45]
DANUBE (DT vs C - all population), 2020 2.78 [0.29; 26.84]
2.98 [0.72 ; 12.39 ] CheckMate 274 (all population), 2017, DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020 3 0% 2,010 moderate not evaluable Increased lipase level TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 6.46 [0.79; 52.82]
DANUBE (DT vs C - all population), 2020 15.41 [2.03; 116.88]
JAVELIN Bladder 100 (all population), 2020 20.63 [1.20; 354.60]
11.75 [3.21 ; 43.03 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, JAVELIN Bladder 100 (all population), 2020 3 0% 2,000 moderate not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
DANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53]
JAVELIN Bladder 100 (all population), 2020 6.06 [0.30; 121.47]
KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
1.84 [0.30 ; 11.19 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017 4 0% 2,521 moderate not evaluable Leucopenia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.04 [0.00; 0.62]
DANUBE (DT vs C - all population), 2020 0.04 [0.00; 0.63]
KEYNOTE-361 (P vs C), 2021 0.01 [0.00; 0.13]
KEYNOTE-361 (PC vs C), 2021 0.68 [0.38; 1.24]
0.07 [0.01 ; 0.76 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 4 81% 2,646 moderate not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
3.98 [0.18 ; 88.64 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
DANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53]
KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
1.84 [0.31 ; 10.77 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 4 0% 2,646 moderate not evaluable Myositis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35]
DANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53]
JAVELIN Bladder 100 (all population), 2020 4.03 [0.18; 89.68]
KEYNOTE-045 (all population), 2017 0.48 [0.02; 14.32]
KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
KEYNOTE-361 (PC vs C), 2021 0.98 [0.02; 49.53]
1.33 [0.31 ; 5.70 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 6 0% 3,856 moderate not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
DANUBE (D vs C - all population), 2020 0.06 [0.00; 0.97]
DANUBE (DT vs C - all population), 2020 0.11 [0.01; 0.90]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.73 [0.31; 9.49]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.27 [0.01; 6.11]
JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
KEYNOTE-045 (all population), 2017 0.24 [0.03; 2.13]
KEYNOTE-361 (P vs C), 2021 0.28 [0.06; 1.32]
KEYNOTE-361 (PC vs C), 2021 0.85 [0.31; 2.38]
0.47 [0.23 ; 0.97 ] CheckMate 274 (all population), 2017, DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 9 13% 6,142 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
DANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15]
JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
KEYNOTE-045 (all population), 2017 3.86 [0.17; 85.92]
KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
2.30 [0.65 ; 8.21 ] CheckMate 274 (all population), 2017, DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 7 0% 4,555 moderate serious Neutropenia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.01 [0.00; 0.09]
DANUBE (DT vs C - all population), 2020 0.01 [0.00; 0.09]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.01 [1.12; 3.62]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.03 [0.00; 0.52]
IMvigor-211 (all population), 2018 0.04 [0.01; 0.15]
IMvigor-211 (PDL1>5%), 2018 0.20 [0.04; 0.97]
KEYNOTE-045 (all population), 2017 0.01 [0.00; 0.19]
KEYNOTE-361 (P vs C), 2021 0.00 [0.00; 0.07]
KEYNOTE-361 (PC vs C), 2021 0.94 [0.67; 1.32]
0.07 [0.02 ; 0.26 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 9 90% 5,882 moderate serious Pancreatitis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
DANUBE (DT vs C - all population), 2020 3.70 [0.17; 82.33]
JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
KEYNOTE-361 (P vs C), 2021 4.55 [0.20; 101.37]
KEYNOTE-361 (PC vs C), 2021 3.94 [0.18; 87.61]
2.88 [0.66 ; 12.51 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 5 0% 3,335 moderate serious Pancytopenia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.11 [0.01; 2.13]
DANUBE (DT vs C - all population), 2020 0.11 [0.01; 2.16]
0.11 [0.01 ; 0.91 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020 2 0% 1,311 moderate not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.12 [0.01; 0.95]
IMvigor-211 (PDL1>5%), 2018 0.32 [0.03; 3.14]
KEYNOTE-045 (all population), 2017 0.24 [0.01; 5.31]
0.20 [0.05 ; 0.78 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 3 0% 1,649 moderate not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
DANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15]
JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
KEYNOTE-045 (all population), 2017 9.75 [0.53; 179.40]
KEYNOTE-361 (P vs C), 2021 4.58 [0.51; 41.18]
KEYNOTE-361 (PC vs C), 2021 2.96 [0.31; 28.57]
3.48 [1.20 ; 10.09 ] CheckMate 274 (all population), 2017, DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 7 0% 4,555 moderate not evaluable Pruritic rash TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
DANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15]
1.24 [0.14 ; 10.61 ] CheckMate 274 (all population), 2017, DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020 3 0% 2,010 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
DANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35]
DANUBE (DT vs C - all population), 2020 3.70 [0.17; 82.33]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.72 [0.06; 51.51]
IMvigor-130 (At-arm B vs Ch-armC), 2020 1.10 [0.02; 55.68]
JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
KEYNOTE-045 (all population), 2017 0.48 [0.02; 14.32]
KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
KEYNOTE-361 (PC vs C), 2021 5.92 [0.30; 118.67]
1.80 [0.57 ; 5.67 ] CheckMate 274 (all population), 2017, DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 9 0% 6,142 moderate serious Pyrexia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.23 [0.01; 5.02]
DANUBE (DT vs C - all population), 2020 0.92 [0.13; 6.57]
JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
0.66 [0.14 ; 3.06 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, JAVELIN Bladder 100 (all population), 2020 3 0% 2,000 moderate not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
DANUBE (D vs C - all population), 2020 3.64 [0.16; 81.12]
DANUBE (DT vs C - all population), 2020 7.44 [0.39; 141.31]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.86 [0.02; 43.49]
IMvigor-130 (At-arm B vs Ch-armC), 2020 4.43 [0.20; 98.49]
JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
KEYNOTE-361 (P vs C), 2021 0.57 [0.02; 16.92]
KEYNOTE-361 (PC vs C), 2021 3.95 [0.44; 35.56]
2.97 [1.02 ; 8.67 ] CheckMate 274 (all population), 2017, DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 8 0% 5,621 moderate not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 274 (all population), 2017 8.01 [0.42; 152.12]
8.01 [0.42 ; 152.12 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 274 (all population), 2017 5.99 [0.30; 120.06]
5.99 [0.30 ; 120.06 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Sarcoidosis TRAE (grade 3-4)detailed results KEYNOTE-361 (P vs C), 2021 1.13 [0.02; 57.26]
KEYNOTE-361 (PC vs C), 2021 0.98 [0.02; 49.53]
1.05 [0.07 ; 16.88 ] KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 2 0% 1,335 moderate not evaluable Sepsis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.06; 14.56]
DANUBE (DT vs C - all population), 2020 0.46 [0.02; 13.75]
0.69 [0.08 ; 5.93 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020 2 0% 1,311 moderate not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.32 [0.03; 3.07]
KEYNOTE-361 (P vs C), 2021 1.13 [0.16; 8.10]
KEYNOTE-361 (PC vs C), 2021 3.99 [0.84; 18.92]
1.36 [0.32 ; 5.68 ] KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 3 41% 1,856 moderate not evaluable Stevens-Johnson syndrome TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 1.82 [0.06; 54.35]
DANUBE (DT vs C - all population), 2020 0.92 [0.02; 46.53]
1.36 [0.10 ; 17.71 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020 2 0% 1,311 moderate not evaluable Stomatitis TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
DANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15]
1.36 [0.10 ; 17.75 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020 2 0% 1,311 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.02 [0.00; 0.29]
DANUBE (DT vs C - all population), 2020 0.02 [0.00; 0.29]
IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.11 [0.55; 2.26]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.08 [0.01; 0.58]
KEYNOTE-361 (P vs C), 2021 0.02 [0.00; 0.13]
KEYNOTE-361 (PC vs C), 2021 0.80 [0.52; 1.24]
0.14 [0.04 ; 0.51 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 6 85% 4,233 moderate serious Thyroiditis TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
DANUBE (D vs C - all population), 2020 0.91 [0.02; 45.86]
DANUBE (DT vs C - all population), 2020 1.84 [0.06; 55.15]
JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
KEYNOTE-361 (P vs C), 2021 2.27 [0.08; 67.88]
KEYNOTE-361 (PC vs C), 2021 0.98 [0.02; 49.53]
1.26 [0.30 ; 5.18 ] CheckMate 274 (all population), 2017, DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 7 0% 4,555 moderate serious Urticaria TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Uveitis TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Vitiligo TRAE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 1.00 [0.02; 50.69]
1.00 [0.02 ; 50.69 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Vomiting TRAE (grade 3-4)detailed results DANUBE (D vs C - all population), 2020 0.09 [0.00; 1.64]
DANUBE (DT vs C - all population), 2020 0.36 [0.07; 1.89]
KEYNOTE-361 (P vs C), 2021 0.14 [0.02; 1.12]
KEYNOTE-361 (PC vs C), 2021 1.11 [0.42; 2.90]
0.40 [0.12 ; 1.27 ] DANUBE (D vs C - all population), 2020, DANUBE (DT vs C - all population), 2020, KEYNOTE-361 (P vs C), 2021, KEYNOTE-361 (PC vs C), 2021 4 45% 2,646 moderate not evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 2.01 [0.07; 60.08]
2.01 [0.07 ; 60.08 ] JAVELIN Bladder 100 (all population), 2020 1 0% 689 NA not evaluable Abdominal pain AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.40 [0.10; 1.58]
0.40 [0.10 ; 1.58 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Acute kidney injury AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 2.27 [0.58; 8.88]
2.27 [0.58 ; 8.88 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Alopecia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.16 [0.01; 3.17]
0.16 [0.01 ; 3.17 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Anaemia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.08 [0.82; 1.42]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.08 [0.05; 0.13]
JAVELIN Bladder 100 (all population), 2020 1.32 [0.57; 3.04]
KEYNOTE-045 (all population), 2017 0.65 [0.37; 1.16]
0.51 [0.14 ; 1.84 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017 4 96% 2,797 moderate not evaluable Arthralgia AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 4.03 [0.18; 89.68]
KEYNOTE-045 (all population), 2017 0.16 [0.01; 3.17]
0.78 [0.03 ; 18.57 ] JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017 2 54% 1,210 moderate not evaluable Asthenia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.43 [0.81; 2.50]
IMvigor-130 (At-arm B vs Ch-armC), 2020 0.51 [0.24; 1.10]
JAVELIN Bladder 100 (all population), 2020 0.12 [0.01; 2.36]
KEYNOTE-045 (all population), 2017 0.14 [0.03; 0.63]
0.48 [0.16 ; 1.41 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020, IMvigor-130 (At-arm B vs Ch-armC), 2020, JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017 4 75% 2,797 moderate not evaluable Back pain AE (grade 3-4)detailed results JAVELIN Bladder 100 (all population), 2020 0.50 [0.15; 1.66]
KEYNOTE-045 (all population), 2017 1.92 [0.17; 21.35]
0.65 [0.22 ; 1.92 ] JAVELIN Bladder 100 (all population), 2020, KEYNOTE-045 (all population), 2017 2 0% 1,210 moderate not evaluable Blood and lymphatic system disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.24 [0.15; 0.40]
0.24 [0.15 ; 0.40 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Blood creatinine increased AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.17; 21.35]
1.92 [0.17 ; 21.35 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-08 07:16 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 11,288,153,157,290,155,154,289,188,189,239,158,252,253,76,238,236,237
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,746,745,856,634,861,416,864,769,980,369,743